You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection

Article metrics

Article menu

Download PDFPDF

Poster Presentation
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2024

AbstractFullPdf
Dec 2019010
Jan 2020041
Feb 2020031
May 2020020
Jun 2020070
Jul 2020020
Aug 2020030
Sep 2020070
Nov 2020010
Dec 2020041
Jan 2021041
Apr 2021020
Jun 2021020
Jul 2021020
Aug 2021020
Sep 2021010
Oct 2021031
Nov 2021033
Dec 2021040
Jan 2022050
Feb 2022030
Mar 2022021
Apr 2022011
May 2022051
Jun 2022060
Jul 2022031
Aug 2022062
Sep 2022050
Oct 2022022
Nov 2022080
Dec 2022060
Jan 2023010
Feb 20230143
Mar 20230132
Apr 2023021
May 2023030
Jun 2023061
Jul 2023042
Sep 2023020
Oct 2023021
Nov 2023041
Dec 20230102
Jan 2024040
Feb 2024042
Mar 20240330
Apr 2024066
May 2024053
Jun 2024040
Jul 2024041
Aug 2024021
Total020272